30 results
8-K
EX-99.1
APGE
Apogee Therapeutics, Inc.
19 Aug 24
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025
7:29am
inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other … and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic
S-3ASR
APGE
Apogee Therapeutics, Inc.
12 Aug 24
Automatic shelf registration
5:25pm
our programs for the treatment of atopic dermatitis (“AD”), asthma, chronic obstructive pulmonary disease (“COPD”) and related inflammatory … and dosing in the largest inflammatory and immunology (“I&I”) markets, including for the treatment of atopic dermatitis (“AD”), asthma, chronic obstructive
8-K
EX-99.2
APGE
Apogee Therapeutics, Inc.
12 Aug 24
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
6:35am
areata, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, eosinophilic es ophagitis and prurigo nodularis. Higher exposures … = Psoriasis; COPD = Chronic obstructive pulmonary dise ase ; AD = Atopic dermatitis SOURCE: Academic journals, disease foundations, WHO, CDC, census data
8-K
EX-99.1
APGE
Apogee Therapeutics, Inc.
12 Aug 24
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
6:35am
and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I … dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome
8-K
EX-99.1
9sbhihl3fy
28 May 24
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
7:35am
8-K
EX-99.1
2zcl7s
15 May 24
Regulation FD Disclosure
4:39pm
8-K
EX-99.1
h45wfhsdpmlqyy
13 May 24
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
7:05am
DEF 14A
kqqmmnvv lb
24 Apr 24
Definitive proxy
4:15pm
8-K
EX-99.1
3epf0
25 Mar 24
Regulation FD Disclosure
7:30am
8-K
jz81xo43
25 Mar 24
Regulation FD Disclosure
7:30am
424B4
wgbzo7sv
11 Mar 24
Prospectus supplement with pricing info
6:01am
8-K
EX-99.1
23l91ba2v8lw816eg9
5 Mar 24
Regulation FD Disclosure
8:15am
10-K
uvrx6q0myajhftfsmk63
5 Mar 24
Annual report
6:15am
8-K
EX-99.2
5mg54
5 Mar 24
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
6:11am
8-K
EX-99.1
lx9 8l77asq0n
5 Mar 24
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
6:11am
DRS
bf3xc90 fx
9 Feb 24
Draft registration statement
12:00am